严重肢体缺血治疗 (CLI) 市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

Critical Limb Ischemia Treatment (CLI) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月01日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球危重肢体缺血 (CLI) 治疗市场预计 2023 年将价值 42 亿美元，2024 年至 2032 年复合年增长率为 6.7%。疼痛、溃疡和潜在的截肢。由于医疗技术的进步，血管重建手术的结果有所改善，在恢復血流和避免肢体丧失方面发挥关键作用。

此外，血管影像技术的进步提高了诊断 CLI 和规划血管重建的精确度。双功超音波、电脑断层血管摄影 (CTA) 和 MRI 系统等工具可提供复杂的血管影像，这对于评估阻塞严重程度和位置至关重要。这些增强的诊断不仅简化了治疗，也提高了患者的治疗效果。

整个严重肢体缺血治疗产业根据治疗类型、最终用途和地区进行分类。

该市场按治疗类型细分，包括手术、药物和其他治疗。手术领域占据市场主导地位，到2023 年估值将达到29 亿美元。防止肢体丧失和改善预后至关重要。

CLI 治疗产业的最终用途细分包括医院、门诊手术中心等。预计到 2032 年，医院领域将以 7% 的复合年增长率增长。他们提供全方位的护理，从诊断和影像到手术和术后护理。先进的影像工具，包括双功能超音波和 CT 血管造影，使医院能够准确测量动脉阻塞并制定合适的治疗计划。

2023 年，北美 CLI 治疗市场价值为 17 亿美元。该地区与 CLI 相关的危险因子（例如糖尿病和高血压）盛行率升高，刺激了从药物治疗到手术介入等多种治疗选择的强烈需求。

产业生态系统分析
产业影响力
- 成长动力
  - 週边动脉疾病（PAD）盛行率增加
  - 血管重建手术的技术进步
  - 提高认识和早期诊断
- 产业陷阱与挑战
  - 先进治疗费用高
成长潜力分析
技术景观
未来市场趋势
监管环境
产品管道分析
报销场景
波特的分析
差距分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
程式
- 血管内手术
  - 血管成形术
  - 支架置入术
  - 旋切术
- 手术程序
  - 绕道手术
  - 动脉内膜切除术
药物
- 抗血小板药物
- 抗凝血剂
- 降胆固醇药物
- 止痛药
- 其他药物
其他治疗类型

第 6 章：市场估计与预测：按最终用途分类，2021 - 2032 年

主要趋势
医院
门诊手术中心
其他最终用户

第 7 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 8 章：公司简介

Abbott Laboratories
Bayer
Boston Scientific
Cesca Therapeutics
Cook Medical
Eli Lilly and Company
Medtronic plc
Micro Medical Solutions
Pfizer
Sanofi
Terumo Corporation
Teva Pharmaceuticals

简介目录

Product Code: 10560

The Global Critical Limb Ischemia (CLI) Treatment Market, valued at USD 4.2 billion in 2023, is set to grow at a CAGR of 6.7% from 2024 to 2032. CLI, a severe manifestation of peripheral artery disease, restricts blood flow to the limbs, leading to pain, ulcers, and potential limb amputation. Due to advancements in medical technology, revascularization procedures have seen improved outcomes, playing a pivotal role in restoring blood flow and averting limb loss.

Moreover, advancements in vascular imaging technologies have sharpened the precision in diagnosing CLI and planning revascularization. Tools, such as duplex ultrasound, computed tomography angiography (CTA), and MRI systems provide intricate vascular images, crucial for assessing blockage severity and location. These enhanced diagnostics not only streamline treatment but also elevate patient outcomes.

The overall critical limb ischemia treatment industry is categorized based on treatment type, end-use, and region.

The market, segmented by treatment type, includes procedures, medications, and other treatments. Dominating the market, the procedures segment was valued at USD 2.9 billion in 2023. Encompassing revascularization techniques like angioplasty, stent placement, atherectomy, and surgical bypass, this segment is vital for restoring blood flow in CLI patients, preventing limb loss, and enhancing outcomes.

End-use segmentation of the CLI treatment industry includes hospitals, ambulatory surgical centers, and others. The hospitals segment is projected to grow at a 7% CAGR through 2032. As primary venues for CLI diagnosis and treatment, hospitals cater to the complexities of this severe peripheral artery disease. They provide a full spectrum of care, from diagnosis and imaging to surgical and post-operative care. Advanced imaging tools, including duplex ultrasound and CT angiography, empower hospitals to gauge arterial blockages accurately and devise suitable treatment plans.

North America CLI treatment market was valued at USD 1.7 billion in 2023. North America's leadership in the global CLI treatment arena is underscored by its advanced healthcare system, ensuring widespread access to cutting-edge diagnostic and therapeutic tools. The region's heightened prevalence of CLI-related risk factors, such as diabetes and hypertension, fuels a strong demand for diverse treatment options, spanning pharmacological therapies to surgical interventions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of peripheral artery disease (PAD)
  - 3.2.1.2 Technological advancements in revascularization procedures
  - 3.2.1.3 Growing awareness and early diagnosis
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced treatments
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Regulatory landscape
3.7 Product pipeline analysis
3.8 Reimbursement scenario
3.9 Porter's analysis
3.10 GAP analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Procedures
- 5.2.1 Endovascular procedures
  - 5.2.1.1 Angioplasty
  - 5.2.1.2 Stenting
  - 5.2.1.3 Atherectomy
- 5.2.2 Surgical procedures
  - 5.2.2.1 Bypass surgery
  - 5.2.2.2 Endarterectomy
5.3 Medications
- 5.3.1 Antiplatelet drugs
- 5.3.2 Anticoagulants
- 5.3.3 Cholesterol-lowering drugs
- 5.3.4 Pain relievers
- 5.3.5 Other medications
5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospitals
6.3 Ambulatory surgical centers
6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa